549 related articles for article (PubMed ID: 33711340)
21. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
22. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.
Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ
Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological Activation of cGAS for Cancer Immunotherapy.
Garland KM; Rosch JC; Carson CS; Wang-Bishop L; Hanna A; Sevimli S; Van Kaer C; Balko JM; Ascano M; Wilson JT
Front Immunol; 2021; 12():753472. PubMed ID: 34899704
[TBL] [Abstract][Full Text] [Related]
24. DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity.
Kitai Y; Kawasaki T; Sueyoshi T; Kobiyama K; Ishii KJ; Zou J; Akira S; Matsuda T; Kawai T
J Immunol; 2017 Feb; 198(4):1649-1659. PubMed ID: 28069806
[TBL] [Abstract][Full Text] [Related]
25. CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of T
Benoit-Lizon I; Jacquin E; Rivera Vargas T; Richard C; Roussey A; Dal Zuffo L; Martin T; Melis A; Vinokurova D; Shahoei SH; Baeza Garcia A; Pignol C; Giorgiutti S; Carapito R; Boidot R; Végran F; Flavell RA; Ryffel B; Nelson ER; Soulas-Sprauel P; Lawrence T; Apetoh L
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091453
[TBL] [Abstract][Full Text] [Related]
26. Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response.
Li T; Cheng H; Yuan H; Xu Q; Shu C; Zhang Y; Xu P; Tan J; Rui Y; Li P; Tan X
Sci Rep; 2016 Jan; 6():19049. PubMed ID: 26754564
[TBL] [Abstract][Full Text] [Related]
27. Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity.
An M; Yu C; Xi J; Reyes J; Mao G; Wei WZ; Liu H
Nanoscale; 2018 May; 10(19):9311-9319. PubMed ID: 29737353
[TBL] [Abstract][Full Text] [Related]
28. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
Temizoz B; Kuroda E; Ohata K; Jounai N; Ozasa K; Kobiyama K; Aoshi T; Ishii KJ
Eur J Immunol; 2015 Apr; 45(4):1159-69. PubMed ID: 25529558
[TBL] [Abstract][Full Text] [Related]
29. Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response.
Shi F; Su J; Wang J; Liu Z; Wang T
Mol Cell Biochem; 2021 Feb; 476(2):1015-1024. PubMed ID: 33141310
[TBL] [Abstract][Full Text] [Related]
30. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
Corrales L; Gajewski TF
Clin Cancer Res; 2015 Nov; 21(21):4774-9. PubMed ID: 26373573
[TBL] [Abstract][Full Text] [Related]
31. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
[TBL] [Abstract][Full Text] [Related]
32. Refractoriness of STING therapy is relieved by AKT inhibitor through effective vascular disruption in tumour.
Jeong SH; Yang MJ; Choi S; Kim J; Koh GY
Nat Commun; 2021 Jul; 12(1):4405. PubMed ID: 34285232
[TBL] [Abstract][Full Text] [Related]
33. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
Deng L; Liang H; Xu M; Yang X; Burnette B; Arina A; Li XD; Mauceri H; Beckett M; Darga T; Huang X; Gajewski TF; Chen ZJ; Fu YX; Weichselbaum RR
Immunity; 2014 Nov; 41(5):843-52. PubMed ID: 25517616
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic.
Chin EN; Yu C; Vartabedian VF; Jia Y; Kumar M; Gamo AM; Vernier W; Ali SH; Kissai M; Lazar DC; Nguyen N; Pereira LE; Benish B; Woods AK; Joseph SB; Chu A; Johnson KA; Sander PN; Martínez-Peña F; Hampton EN; Young TS; Wolan DW; Chatterjee AK; Schultz PG; Petrassi HM; Teijaro JR; Lairson LL
Science; 2020 Aug; 369(6506):993-999. PubMed ID: 32820126
[TBL] [Abstract][Full Text] [Related]
35. STING activator 2'3'-cGAMP enhanced HSV-1-based oncolytic viral therapy.
Sibal PA; Matsumura S; Ichinose T; Bustos-Villalobos I; Morimoto D; Eissa IR; Abdelmoneim M; Aboalela MAM; Mukoyama N; Tanaka M; Naoe Y; Kasuya H
Mol Oncol; 2024 May; 18(5):1259-1277. PubMed ID: 38400597
[TBL] [Abstract][Full Text] [Related]
36. STING agonists enable antiviral cross-talk between human cells and confer protection against genital herpes in mice.
Skouboe MK; Knudsen A; Reinert LS; Boularan C; Lioux T; Perouzel E; Thomsen MK; Paludan SR
PLoS Pathog; 2018 Apr; 14(4):e1006976. PubMed ID: 29608601
[TBL] [Abstract][Full Text] [Related]
37. The host STING pathway at the interface of cancer and immunity.
Corrales L; McWhirter SM; Dubensky TW; Gajewski TF
J Clin Invest; 2016 Jul; 126(7):2404-11. PubMed ID: 27367184
[TBL] [Abstract][Full Text] [Related]
38. STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice.
Wang Z; Celis E
Cancer Immunol Immunother; 2015 Aug; 64(8):1057-66. PubMed ID: 25986168
[TBL] [Abstract][Full Text] [Related]
39. A cell-based high throughput screening assay for the discovery of cGAS-STING pathway agonists.
Liu B; Tang L; Zhang X; Ma J; Sehgal M; Cheng J; Zhang X; Zhou Y; Du Y; Kulp J; Guo JT; Chang J
Antiviral Res; 2017 Nov; 147():37-46. PubMed ID: 28982551
[TBL] [Abstract][Full Text] [Related]
40. Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy.
Lu ZD; Chen YF; Shen S; Xu CF; Wang J
ACS Appl Mater Interfaces; 2021 Jun; 13(25):29424-29438. PubMed ID: 34129318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
